Vistagen Therapeutics Notifies Nasdaq of Audit Committee Non-Compliance
VTGN sits 36% above its 52-week low of $0.43 on light trading volume (0.3× avg).
Summary
Vistagen Therapeutics, Inc. reported non-compliance with Nasdaq's Audit Committee composition rule following a director's resignation, though its listing is not immediately affected.
Key Events · Corporate Governance and Compliance · VTGN
-
Nasdaq Non-Compliance Notified
Vistagen Therapeutics formally notified Nasdaq of its non-compliance with Listing Rule 5605(c)(2), which requires a minimum of three independent directors on the Audit Committee.
-
Director Resignation Impact
The non-compliance resulted from Ms. Mary Rotunno's resignation from the Board, effective April 1, 2026, reducing the Audit Committee to two members.
-
Cure Period Granted
The company has been granted a cure period to regain compliance, and its common stock listing on The Nasdaq Capital Market is not immediately affected by this specific non-compliance.
-
Context of Existing Distress
This governance issue arises while the company is already facing substantial doubt about its ability to continue as a going concern and a broader Nasdaq delisting threat, as previously reported in its last 10-Q.
Analysis · VTGN · Life Sciences
This 8-K filing indicates Vistagen Therapeutics is facing another governance challenge, formally notifying Nasdaq of its non-compliance with the rule requiring at least three independent directors on its Audit Committee. This issue stems from a recent director resignation. While the company has a cure period and its listing is not immediately threatened by this specific non-compliance, it adds to the existing concerns about the company's ability to continue as a going concern and its broader Nasdaq delisting threat, as previously disclosed in its last 10-Q. Investors should monitor the company's progress in regaining compliance and its overall financial stability.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VTGN was trading at $0.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.2M. The 52-week trading range was $0.43 to $5.14. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.